Dabur Pharma to sell 73% to EU co’s Singapore unit

Last year, Dabur Pharma had sold its non-oncology drugs business to local rival Alembic to focus on cancer treatment drugs. With Saturday’s announcement, the Dabur Group is now expected to focus fully on its FMCG business, the fourth largest in India.

Founded in March 2003, Dabur Pharma operates in Europe and some other markets through its fully owned subsidiary, Dabur Oncology Plc. The fully integrated pharmaceutical business of Dabur Pharma covers oral and injectable finished dosage forms and active pharmaceutical ingredients and intermediates. The company has its manufacturing units for finished dosage forms at Bordon, UK, and Baddi, India, while active pharmaceutical ingredients (APIs) are manufactured at Kalyani, India, and some products come from Dabur India’ Sahibabad facilities.

Fresenius SE is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home. The Fresenius Group consists of four business segments that are responsible for their own business operations worldwide — Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.